In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...
Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...
En tout temps et en tout lieu l'homme semble avoir fait usage de drogues. La culture du pavot à opium était par exemple connue en Mésopotamie 4 000 ans avant l'ère chrétienne, l'utilisation de la ...
Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback